Effect of different schemes of androgen deprivation therapy on bone mass density in prostate cancer patients.

Autores de IIS La Fe

• Karla Romelia Arevalo Ruales

  Autor

• José Ivorra Cortés

  Autor

• Elena Grau García

  Autor

• 

  César David Vera Donoso

  Autor

• Antonio José Cañada Martinez

  Autor

• 

  José Andrés Román Ivorra

  Autor

Grupos

• Núcleo de investigación traslacional integrado Urológico de Valencia (NITIUV)

  

  Leader

  César David Vera Donoso

• Reumatología

  

  Leader

  José Andrés Román Ivorra

Abstract

OBJECTIVES: To evaluate the aspects of the basal bone health status in prostate cancer patients. Furthermore, to evaluate in a real-world setting the effect of different schemes (intermittent or continuous) of androgen deprivation therapy (ADT) and the effect of denosumab in bone mass density (BMD). METHODS: Observational, retrospective study of a cohort of prostate cancer patients in treatment with luteinizing hormone-releasing hormone (LH-RH) agonists, evaluated in the rheumatology department of a tertiary center. Demographics, FRAX score, LH-RH treatment scheme, osteoporosis treatment, laboratory data and BMD were collected. Mixed effect regression models to analyze the interaction between LH-RH treatment scheme, denosumab and BMD evolution were used. RESULTS: Eighty-three patients (mean age 71±8years) were included. At the basal evaluation, 16% of patients presented densitometric osteoporosis and 27% of patients presented high fracture risk. Eighty percent of patients had inadequate vitaminD levels. VitaminD >30ng/mL was correlated with higher T-scores. There was no association between LH-RH treatment scheme and BMD evolution, however there was a positive association with denosumab. CONCLUSION: A high proportion of patients presented elevated fracture risk or inadequate vitaminD levels, not previously recognized. Bone health assessment and fracture risk evaluation are convenient in these patients. In a real-world setting, the effect of denosumab in BMD is detected, however the effect of intermittent LH-RH schema treatment is less evident.

Copyright © 2022 Elsevier España, S.L.U. All rights reserved.

Keywords

• Agonistas de hormona liberadora de hormona luteinizante; Bone mass densitometry; Cáncer de próstata; Densidad mineral ósea; Intermitencia; Intermittent; LH-RH agonists; Osteoporosis; Prostate cancer